AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Uniqure NV (NASDAQ:QURE)
14.46 USD
-0.650 4.302%Sponsored Reports
Loading...
| Previous Close (in USD) | 15.11 |
|---|---|
| Change | -0.650 4.302% |
| 52 W H/L (in USD) | 19.180/3.730 |
| EBITDA (in USD) | -157.584M |
| PE Ratio | -- |
| Volume | 736653 |
| Diluted Eps TTM | -4.38 |
| Total Assets (in USD) | 556.536M |
|---|---|
| Total Liabilities (in USD) | 563.288M |
| Revenue TTM (in USD) | 20.201M |
| Cash (in USD) | 158.93M |
| Market Cap (in USD) | 750.055 M |
| Revenue Per Share TTM | 0.405 |
| Gross Profit TTM (in USD) | -125.126M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Uniqure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Employees: 209
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Matthew Craig Kapusta | CEO & Exec. Director | 1972 |
| 2. | Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site | 1973 |
| 3. | Mr. Pierre Caloz | Chief Operating Officer | NA |
| 4. | Dr. Alexander E. Kuta Ph.D. | Exec. VP of Quality & Regulatory Affairs | 1960 |
| 5. | Dr. Ricardo Dolmetsch Ph.D. | Pres of R&D | 1969 |
| 6. | Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | NA |
| 7. | Mr. David Cerveny | Chief Legal Officer, Gen. Counsel & Sec. | 1967 |
| 8. | Dr. Tamara Tugal Ph.D., MBA | Bus. Devel. Director | NA |
| 9. | Ms. Erin Boyer | Chief People & Culture Office | NA |
| 10. | Ms. Maria E. Cantor | Chief Corp. Affairs Officer | 1968 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-2.380 3.090% | 75.51 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-3.160 4.035% | 77.64 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-2.280 0.506% | 449.43 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.845 0.736% | 519.27 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Income Before Tax | -237.127M | -306.557M | -128.259M | 332.806M | -141.443M |
| Minority Interest | - | - | - | - | - |
| Net Income | -239.556M | -308.478M | -126.789M | 329.589M | -125.024M |
| Selling General Administrative | 50.682M | 75.36M | 55.059M | 57.166M | 42.58M |
| Gross Profit | 8.792M | 2.215M | 103.14M | 499.026M | -84.886M |
| Reconciled Depreciation | 12.641M | 10.043M | 8.537M | 7.299M | 10.648M |
| Ebit | -173.386M | -265M | -116.555M | 311.701M | -137.618M |
| Ebitda | -160.745M | -253.1M | -108.018M | 319M | -126.97M |
| Depreciation And Amortization | 12.641M | 11.9M | 8.537M | 7.299M | 10.648M |
| Operating Income | -184.294M | -282.871M | -143.159M | 310.618M | -125.426M |
| Other Operating Expenses | 197.706M | 298.714M | 249.642M | 213.384M | 162.94M |
| Interest Expense | 63.741M | 41.557M | 11.704M | 7.474M | 3.825M |
| Tax Provision | 2.429M | -1.32M | -1.47M | 3.217M | -16.419M |
| Interest Income | 21.415M | 12.885M | 0.609M | 0.162M | 0.938M |
| Net Interest Income | -42.326M | -16.386M | -11.095M | -7.312M | -2.887M |
| Income Tax Expense | 2.429M | 1.921M | -1.47M | 3.217M | -16.419M |
| Total Revenue | 27.119M | 15.843M | 106.483M | 524.002M | 37.514M |
| Total Operating Expenses | 193.086M | 285.086M | 246.299M | 188.408M | 162.94M |
| Cost Of Revenue | 18.327M | 13.628M | 3.343M | 24.976M | 122.4M |
| Total Other Income Expense Net | -52.833M | -23.686M | 14.9M | 22.188M | -16.017M |
| Net Income From Continuing Ops | -239.556M | -228.465M | -126.789M | 329.589M | -125.024M |
| Net Income Applicable To Common Shares | - | - | -126.789M | 329.589M | -125.024M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Total Assets | 556.536M | 831.689M | 704.964M | 809.18M | 340.395M |
| Intangible Assets | 71.043M | 60.481M | 58.778M | 62.686M | 3.361M |
| Other Current Assets | 16.887M | 2.655M | 2.814M | 2.675M | 3.024M |
| Total Liab | 563.288M | 624.019M | 228.955M | 213.404M | 96.49M |
| Total Stockholder Equity | -6.752M | 207.67M | 476.009M | 595.776M | 243.905M |
| Other Current Liab | 29.225M | 29.648M | 56.553M | 28.487M | 15.956M |
| Common Stock | 2.945M | 2.883M | 2.838M | 2.802M | 2.711M |
| Capital Stock | 2.945M | 2.883M | 2.838M | 2.802M | 2.711M |
| Retained Earnings | -1129.965M | -890.409M | -581.931M | -455.142M | -784.731M |
| Good Will | 22.414M | 26.379M | 25.581M | 27.633M | 0.542M |
| Other Assets | - | - | 20.589M | 21.544M | 45.253M |
| Cash | 158.93M | 241.36M | 228.012M | 556.256M | 244.932M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 40.053M | 73.675M | 75.919M | 36.763M | 27.334M |
| Current Deferred Revenue | - | 29.097M | - | - | 2.082M |
| Net Debt | -92.869M | -102.951M | -85.12M | -420.532M | -173.388M |
| Short Term Debt | 3.601M | 8.344M | 8.382M | 5.774M | 5.524M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 66.061M | 138.409M | 142.892M | 135.724M | 71.544M |
| Other Stockholder Equity | 1173.068M | 1148.749M | 1113.393M | 1076.972M | 1016.018M |
| Property Plant Equipment | - | - | 83.258M | 43.505M | 32.328M |
| Total Current Assets | 390.289M | 651.853M | 476.774M | 628.239M | 258.911M |
| Long Term Investments | 27.464M | 0M | 39.984M | - | - |
| Short Term Investments | 208.591M | 376.532M | 124.831M | - | - |
| Net Receivables | 5.881M | 4.193M | 102.376M | 58.768M | 6.618M |
| Long Term Debt | 51.324M | 101.749M | 102.791M | 100.963M | 35.617M |
| Inventory | 0M | 12.024M | 6.924M | 10.54M | 4.337M |
| Accounts Payable | 7.227M | 6.586M | 10.984M | 2.502M | 3.772M |
| Accumulated Other Comprehensive Income | -52.8M | -53.553M | -58.291M | -28.856M | 9.907M |
| Non Currrent Assets Other | 1.399M | 5.363M | 6.061M | 5.897M | 2.748M |
| Non Current Assets Total | 166.247M | 179.836M | 228.19M | 180.941M | 81.484M |
| Capital Lease Obligations | 14.737M | 36.66M | 40.101M | 34.761M | 35.927M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 |
|---|---|---|---|---|---|
| Investments | 162.968M | -433.46M | -182.734M | -67.387M | -9.484M |
| Total Cashflows From Investing Activities | - | - | -182.734M | -67.387M | -9.484M |
| Total Cash From Financing Activities | -59.486M | 362.721M | 1.445M | 94.858M | 7.444M |
| Net Income | -239.556M | -308.478M | -126.789M | 329.589M | -125.024M |
| Change In Cash | -84.215M | 13.371M | -328.18M | 311.673M | -133.046M |
| Begin Period Cash Flow | 244.544M | 231.173M | 559.353M | 247.68M | 380.726M |
| End Period Cash Flow | 160.329M | 244.544M | 231.173M | 559.353M | 247.68M |
| Total Cash From Operating Activities | -182.728M | -145.929M | -145.06M | 287.959M | -134.828M |
| Depreciation | 12.641M | 11.9M | 8.537M | 7.299M | 10.648M |
| Other Cashflows From Investing Activities | 174.657M | - | -163.146M | -49.949M | -2.213M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | 2.421M | -6.74M | -6.924M | -6.924M | 6.967M |
| Sale Purchase Of Stock | - | - | - | 32.363M | 7.444M |
| Other Cashflows From Financing Activities | -8.559M | 362.413M | -182.734M | 32.363M | -9.484M |
| Capital Expenditures | 3.368M | 7.154M | 17.688M | 17.438M | 9.484M |
| Change In Working Capital | -3.944M | 81.123M | -43.384M | -50.482M | -6.469M |
| Other Non Cash Items | 19.5M | 32.512M | -16.158M | -27.292M | -19.395M |
| Free Cash Flow | -186.096M | -153.083M | -162.748M | 270.521M | -144.312M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Franklin Biotechnology Discv A(acc)USD | 1 month ago | 1254100 |
| 2. | abrdn Healthcare Investors | 1 month ago | 1251520 |
| 3. | SPDR® S&P Biotech ETF | 1 month ago | 987123 |
| 4. | International Biotechnology Ord | 1 month ago | 800172 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 787874 |
| 6. | Macquarie Healthcare I | 2 months ago | 706166 |
| 7. | Franklin Biotechnology Discovery A | 1 month ago | 696400 |
| 8. | abrdn Life Sciences Investors | 1 month ago | 584297 |
| 9. | abrdn World Healthcare | 2 months ago | 523608 |
| 10. | Fidelity Select Biotechnology | 2 months ago | 421282 |
| 11. | Fidelity Select Pharmaceuticals Port | 2 months ago | 405300 |
| 12. | Columbia Small Cap Value I | 2 months ago | 383090 |
| 13. | Columbia Small Cap Value I A | 1 month ago | 383090 |
| 14. | Strategic Advisers Fidelity US TtlStk | 2 months ago | 348400 |
| 15. | iShares Biotechnology ETF | 1 month ago | 300530 |
| 16. | Fidelity Extended Market Index | 2 months ago | 274911 |
| 17. | JPM Thematics Genetic Thrps C2 dist USD | 1 month ago | 262325 |
| 18. | Schwab US Small-Cap ETF™ | 1 month ago | 234496 |
| 19. | Invesco Dorsey Wright SmallCap Momt ETF | 1 month ago | 198187 |
| 20. | Invesco Dorsey Wright Healthcare MomtETF | 1 month ago | 190447 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | RTW INVESTMENTS, LLC | 2 months ago | 4265428 |
| 2. | EcoR1 Capital, LLC | 5 months ago | 3400000 |
| 3. | Vestal Point Capital LP | 5 months ago | 3025000 |
| 4. | Nantahala Capital Management, LLC | 2 months ago | 2755962 |
| 5. | Aberdeen Group PLC | 2 months ago | 2215551 |
| 6. | venBio Select Advisor LLC | 2 months ago | 2175000 |
| 7. | Franklin Resources Inc | 2 months ago | 1987688 |
| 8. | Point72 Asset Management, L.P. | 5 months ago | 1771352 |
| 9. | 683 Capital Management LLC | 5 months ago | 1525000 |
| 10. | BlackRock Inc | 2 months ago | 1436981 |
| 11. | Integral Health Asset Management, LLC | 2 months ago | 1250000 |
| 12. | State Street Corp | 2 months ago | 1229589 |
| 13. | FMR Inc | 2 months ago | 1200944 |
| 14. | Schroder Investment Management Group | 2 months ago | 1190121 |
| 15. | Vanguard Group Inc | 2 months ago | 945466 |
| 16. | Two Sigma Investments LLC | 2 months ago | 916499 |
| 17. | Catalio Capital Management, LP | 2 months ago | 830325 |
| 18. | Boxer Capital Management, LLC | 5 months ago | 750000 |
| 19. | StemPoint Capital LP | 2 months ago | 731039 |
| 20. | Marshall Wace Asset Management Ltd | 5 months ago | 729417 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...